[go: up one dir, main page]

Pepys et al., 2007 - Google Patents

Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy

Pepys et al., 2007

Document ID
4479237145282756584
Author
Pepys M
Tennent G
Booth D
Bellotti V
Lovat L
Tan S
Persey M
Hutchinson W
Booth S
Madhoo S
Soutart A
Hawkins P
Van Zyl‐Smit R
Campistol J
Fraser P
Radford S
Robinson C
Sunde M
Serpell L
Blake C
Publication year
Publication venue
Ciba Foundation Symposium 199‐The Nature and Origin of Amyloid Fibrils: The Nature and Origin of Amyloid Fibrils: Ciba Foundation Symposium 199

External Links

Snippet

Amyloid deposits regress when the supply of fibril precursor proteins is sufficiently reduced, indicating that amyloid fibrils are degradable in vivo. Serum amyloid P component (SAP), a universal constituent of amyloid deposits, efficiently protects amyloid fibrils from proteolysis …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Teplow Structural and kinetic features of amyloid β-protein fibrillogenesis
Maggio et al. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide.
Kisilevsky et al. AßT Amyloidogenesis: Unique, or Variation on a Systemic Theme
Ancsin Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit
Kirkitadze et al. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis
Eisenberg et al. The amyloid state of proteins in human diseases
Mandelkow et al. Biochemistry and cell biology of tau protein in neurofibrillary degeneration
Soto Unfolding the role of protein misfolding in neurodegenerative diseases
Hauser et al. Apolipoprotein E: from lipid transport to neurobiology
DE69637199T2 (en) PEPTIDES AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM TO TREAT DISORDERS AND DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FILLING IN AMYLOID OR AMYLOID-RELATED DEPOSITS
Ji et al. Amyloid β40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice
US20230192787A1 (en) Diagnosis methods, diagnostic agents, and therapeutic agents against alzheimer's disease and frontotemporal lobar degeneration, and screening methods for these agents
Morgado et al. Lipids in amyloid-β processing, aggregation, and toxicity
Arrasate et al. Role of glycosaminoglycans in determining the helicity of paired helical filaments
Schwarzman et al. Interaction of transthyretin with amyloid β‐protein: binding and inhibition of amyloid formation
Maggie et al. Brain amyloid—a physicochemical perspective
Kang et al. Cellular biology of tau diversity and pathogenic conformers
Janus Vaccines for Alzheimer’s disease: how close are we?
Pepys et al. Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy
Kiuchi et al. Disassembly of amyloid β-protein fibril by basement membrane components
Mahakud et al. Amyloids on membrane interfaces: implications for neurodegeneration
Walsh et al. The many faces of Aβ: structures and activity
Westermark et al. Ageing and amyloid fibrillogenesis: Lessons from apolipoprotein Al, transthyretin and islet amyloid polypeptide
Jeyashekar et al. Protein amyloidose misfolding: mechanisms, detection, and pathological implications
Vogels et al. Tau pathology in neurodegenerative diseases